Important Safety Information
Stanozolol was FDA-approved for hereditary angioedema but the oral tablet product has been discontinued in the United States. Anabolic steroids have not been shown to enhance athletic ability, and non-medical use for physique or performance enhancement falls outside approved indications.
Stanozolol is a 17-alpha-alkylated compound, a structural class associated with hepatotoxicity. Liver function should be periodically assessed during medical use, and the drug should be discontinued if liver function abnormalities appear.
Important
Non-Medical Use
Stanozolol has been discontinued as an oral prescription product in the United States. Non-medical use falls outside approved indications and carries significant health risks including hepatotoxicity, cardiovascular strain, and endocrine suppression. Product strength and laboratory verification do not establish safety for human consumption.
Potential Adverse Effects
Hepatotoxicity: As a 17-alpha-alkylated steroid, stanozolol places stress on liver cells. Elevated liver enzymes, cholestatic jaundice, and in rare cases hepatic neoplasms have been reported with this class of compounds.
Cardiovascular effects: Stanozolol can decrease HDL cholesterol and increase LDL cholesterol, potentially accelerating atherosclerosis. Blood pressure elevation is also possible.
Androgenic effects: Acne, accelerated male-pattern hair loss, and increased body hair growth are possible. In women, virilization signs including voice deepening, hirsutism, and clitoromegaly may occur and can be irreversible.
Endocrine suppression: Stanozolol suppresses endogenous testosterone production. A study of healthy males given 10 mg daily for 14 days found a 55% reduction in serum testosterone levels, with reductions in free testosterone, SHBG, and LH.
Musculoskeletal effects: Joint dryness and pain are commonly reported in non-medical contexts, likely related to reduced synovial fluid and collagen synthesis.
Conditions Requiring Medical Evaluation
Stanozolol is contraindicated in known or suspected carcinoma of the prostate or male breast, carcinoma of the breast in females with hypercalcemia, pregnancy, nephrosis, and hypercalcemia. Caution is required in patients with a history of cardiovascular disease, liver disease, or risk factors for either.
Monitoring During Therapy
Medically supervised stanozolol therapy typically involves periodic laboratory assessment. Liver function tests, cholesterol profile, and hemoglobin/hematocrit should be monitored. Because stanozolol can affect glucose metabolism and clotting, blood glucose and coagulation parameters may also be relevant in some patients.
Product Care
Storage & Handling
Store in a cool, dry place away from direct light and moisture. Keep the product in its original packaging and out of the reach of children.
Further Safety Information